Cobimetinib
mRNA synthesis
In vitro transcription of capped mRNA with modified nucleotides and Poly(A) tail
Tyramide Signal Amplification (TSA)
TSA (Tyramide Signal Amplification), used for signal amplification of ISH, IHC and IC etc.
Phos Binding Reagent Acrylamide
Separation of phosphorylated and non-phosphorylated proteins without phospho-specific antibody
Cell Counting Kit-8 (CCK-8)
A convenient and sensitive way for cell proliferation assay and cytotoxicity assay
SYBR Safe DNA Gel Stain
Safe and sensitive stain for visualization of DNA or RNA in agarose or acrylamide gels.
Inhibitor Cocktails
Protect the integrity of proteins from multiple proteases and phosphatases for different applications.
Cobimetinib是丝裂原活化蛋白激酶激酶(MEK)选择性抑制剂,其IC50值为0.9 nM[1]。
MEK是一种激酶,选择性磷酸化丝氨酸/苏氨酸和酪氨酸残基,并参与丝裂原活化蛋白激酶(MAPK)信号转导通路,从而调控细胞增殖、存活、分化、移动和血管生成[2]。
在同时携带KRAS G13D和B-RAF G464V突变的MDA-MB-231T乳腺癌细胞中,Cobimetinib抑制MEK,其IC50值为0.2 nM[1]。在药代动力学-药效学(PK-PD)模型中, Cobimetinib在肿瘤内的停留时间比在血浆中更长,显示出持续的持续的肿瘤药效学应答[3]。
在WM-266-4异种移植小鼠中,Cobimetinib可以减少肿瘤中的pERK,其IC50值分别为0.78 mM(WM-266-4)和0.52 mM。此外,Cobimetinib(3.89 mM)增加WM-266-4小鼠的IC50值。在A375异种移植物小鼠中,Cobimetinib(0.3 ~ 30 mg/kg)呈剂量依赖性地抑制肿瘤。目前,Cobimetinib作为一种潜在的抗肿瘤剂,正处于I期临床试验[3]。
参考文献:
[1]. Rice KD, Aay N, Anand NK, et al. Novel Carboxamide-Based Allosteric MEK Inhibitors: Discovery and Optimization Efforts toward XL518 (GDC-0973). ACS Med Chem Lett, 2012, 3(5): 416-421.
[2]. Akinleye A, Furqan M, Mukhi N, et al. MEK and the inhibitors: from bench to bedside. J Hematol Oncol, 2013, 6: 27.
[3]. Wong H, Vernillet L, Peterson A, et al. Bridging the gap between preclinical and clinical studies using pharmacokinetic-pharmacodynamic modeling: an analysis of GDC-0973, a MEK inhibitor. Clin Cancer Res, 2012, 18(11): 3090-3099.
- 1. Seoyul Lee, Wookyeom Yang, et al. "Inhibition of MEK-ERK pathway enhances oncolytic vaccinia virus replication in doxorubicin-resistant ovarian cancer." Mol Ther Oncolytics. 2022 Apr 18;25:211-224. PMID: 35592390
- 2. Julia C Gutjahr, Elisabeth Bayer, et al. "CD44 Engagement Enhances Acute Myeloid Leukemia Cell Adhesion To The Bone Marrow Microenvironment By Increasing VLA-4 Avidity." Haematologica. 2020 Jul 2; haematol.2019.231944. PMID: 32616529
- 3. White SM, Avantaggiati ML, et al. "YAP/TAZ Inhibition Induces Metabolic and Signaling Rewiring Resulting in Targetable Vulnerabilities in NF2-Deficient Tumor Cells." Dev Cell. 2019 May 6;49(3):425-443.e9. PMID: 31063758
- 4. Kulshrestha A, Katara GK, et al. "Targeting V-ATPase Isoform Restores Cisplatin Activity in Resistant Ovarian Cancer: Inhibition of Autophagy, Endosome Function, and ERK/MEK Pathway." J Oncol. 2019 Apr 1;2019:2343876. PMID: 31057611
- 5. Brunen D, de Vries RC, et al. "PIM Kinases Are a Potential Prognostic Biomarker and Therapeutic Target in Neuroblastoma." Mol Cancer Ther. 2018 Apr;17(4):849-857. PMID: 29440296
- 6. Gutjahr JC, Szenes E, et al. "Microenvironment-induced CD44v6 promotes early disease progression in chronic lymphocytic leukemia." Blood. 2018 Mar 22;131(12):1337-1349. PMID: 29352038
Storage | Store at -20°C |
M.Wt | 531.31 |
Cas No. | 934660-93-2 |
Formula | C21H21F3IN3O2 |
Synonyms | GDC-0973;XL-518;GDC 0973;XL 518;GDC0973;XL518 |
Solubility | ≥26.55 mg/mL in DMSO; insoluble in H2O; ≥33.53 mg/mL in EtOH with gentle warming |
Chemical Name | [3,4-difluoro-2-(2-fluoro-4-iodoanilino)phenyl]-[3-hydroxy-3-[(2S)-piperidin-2-yl]azetidin-1-yl]methanone |
SDF | Download SDF |
Canonical SMILES | C1CCNC(C1)C2(CN(C2)C(=O)C3=C(C(=C(C=C3)F)F)NC4=C(C=C(C=C4)I)F)O |
运输条件 | 蓝冰运输或根据您的需求运输。 |
一般建议 | 不同厂家不同批次产品溶解度各有差异,仅做参考。若实验所需浓度过大至产品溶解极限,请添加助溶剂助溶或自行调整浓度。溶液形式一般不宜长期储存,请尽快用完。 |
细胞实验 [1]: | |
细胞系 |
同时携带KRAS G13D和B-RAF G464V突变的MDA-MB-231T乳腺癌细胞系 |
溶解方法 |
在DMSO中的溶解度> 26.6 mg/mL。为了获得更高浓度,可以将离心管在37℃加热10分钟和/或在超声波浴中震荡一段时间。原液可以在-20℃以下储存几个月。 |
反应条件 |
0-10 nM |
应用 |
在生物化学活性c-Raf / MEK1 / ERK研究中,cobimetinib抑制MEK1活性,IC50值为0.9 nM。 另外,在具有KRAS G13D和B-RAF G464V突变体的MDA-MB-231T乳腺癌细胞中,研究发现cobimetinib能够抑制MEK,IC50值为0.2 nM。 |
动物实验 [1]: | |
动物模型 |
MDA-MB-231T小鼠异种移植模型 |
剂量 |
0.3-30 mg/kg,口服,一天一次 |
应用 |
在MDA-MB-231T疗效研究中,cobimetinib在1和3mg / kg下分别显示出60和93%的肿瘤生长抑制率,并且在较高剂量下观察到统计学显著的肿瘤消退。预测出的ED50和ED90值分别为0.6和约3mg / kg /天,后一种情况对应于130 nM范围内的峰值血浆水平。 |
注意事项 |
请测试所有化合物在室内的溶解度,实际溶解度和理论值可能略有不同。这是由实验系统的误差引起的,属于正常现象。 |
References: [1] Rice KD, Aay N, Anand NK, et al. Novel Carboxamide-Based Allosteric MEK Inhibitors: Discovery and Optimization Efforts toward XL518 (GDC-0973). ACS Med Chem Lett, 2012, 3(5): 416-421. |
质量控制和MSDS
- 批次: